Disease · MONDO_0005131
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Concurrent Cisplatin and Radiation vs Concurrent Cisplatin, Tirapazamine and Radiation: serious adverse events | 42 of 190 | 65 of 180 | 370 | NCT00262821 | Trial comparisons |
| S-1 + Cisplatin (Arm A) vs Cisplatin (Arm B): deaths from any cause | 7 of 188 | 3 of 175 | 363 | NCT00770874 | Trial comparisons |
| S-1 + Cisplatin (Arm A) vs Cisplatin (Arm B): serious adverse events | 72 of 188 | 34 of 175 | 363 | NCT00770874 | Trial comparisons |
| Arm I: Cisplatin/Radiation Therapy vs Arm II: Cisplatin/Radiation Therapy + Carboplatin/Paclitaxel: deaths from any cause | 17 of 109 | 13 of 103 | 212 | NCT00980954 | Trial comparisons |
| Arm I: Cisplatin/Radiation Therapy vs Arm II: Cisplatin/Radiation Therapy + Carboplatin/Paclitaxel: serious adverse events | 14 of 107 | 25 of 101 | 208 | NCT00980954 | Trial comparisons |
| Lapatinib Monotherapy vs Pazopanib Monotherapy: Clinical Benefit Response | 7 of 78 | 15 of 74 | 152 | NCT00430781 | Trial comparisons |
| Lapatinib Monotherapy vs Pazopanib Monotherapy: Response | 4 of 78 | 7 of 74 | 152 | NCT00430781 | Trial comparisons |
| PET-Guided Bone Marrow-Sparing IMRT vs IMRT: Progression-free Survival | 46 of 46 | 55 of 55 | 101 | NCT01554397 | Trial comparisons |
| IMRT vs PET-Guided Bone Marrow-Sparing IMRT: deaths from any cause | 0 of 55 | 0 of 46 | 101 | NCT01554397 | Trial comparisons |
| IMRT Arm (Phase II) vs PET-Guided BMS-IMRT (Phase II): Primary Event (Acute Hematologic or GI Toxicity) | 55 of 55 | 46 of 46 | 101 | NCT01554397 | Trial comparisons |
| IMRT vs PET-Guided Bone Marrow-Sparing IMRT: serious adverse events | 0 of 55 | 0 of 46 | 101 | NCT01554397 | Trial comparisons |
| Radiation Therapy Plus Cisplatin vs Radiation Therapy Plus Cisplatin & Amifostine: serious adverse events | 20 of 26 | 12 of 15 | 41 | NCT00012012 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005131/comparisons